New drug cocktail aims to slow advanced liver cancer

NCT ID NCT06860490

Recruiting now Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Apr 28, 2026 · Last updated May 01, 2026 · Updated 1 time

Summary

This study tests whether adding a liver-directed chemotherapy infusion (HAIC) to a combination of two drugs (sintilimab and bevacizumab) can help people with advanced liver cancer live longer without their disease getting worse. About 164 adults with liver cancer that cannot be removed by surgery or treated with local therapies will be randomly assigned to receive the drug combo alone or with HAIC. The main goal is to see how long it takes for the cancer to progress or for death to occur.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Zhongshan Hospital, Fudan University
RECRUITING

Shanghai, Shanghai Municipality, 200032, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

HEPATOCELLULAR CARCINOMA (HCC)